View in EDS

Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.

Saved in:

Bibliographic Details
Title:	Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.
Authors:	Villamañan E; Department of Pharmacy, Hospital Universitario La Paz. IdiPaz, Madrid, Spain., Quirce S; Department of Allergy, Hospital Universitario La Paz. IdiPaz, Madrid, Spain., Torres C; AstraZeneca Farmacéutica Spain S.A., Madrid, Spain. covadonga.torres@astrazeneca.com., Martínez N; Doctoral Program in Biomedical Sciences and Public Health, International Doctorate Program, National University of Distance Education (UNED), Institute of Health Carlos III (IMIENS), Madrid, Spain., Garí C; Outcomes'10 (A ProductLife Group Company), Castellón de la Plana, Spain., Vidal-Vilar N; Outcomes'10 (A ProductLife Group Company), Castellón de la Plana, Spain., Almonacid C; Department of Respiratory Medicine, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Source:	PharmacoEconomics - open [Pharmacoecon Open] 2026 Jul 01. Date of Electronic Publication: 2026 Jul 01.
Publication Type:	Journal Article
Journal Info:	Publisher: Springer International Publishing AG Country of Publication: Switzerland NLM ID: 101700780 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2509-4254 (Electronic) Linking ISSN: 25094262 NLM ISO Abbreviation: Pharmacoecon Open
Database:	MEDLINE Ultimate

Description
ISSN:	2509-4254
DOI:	10.1007/s41669-026-00667-6